Khang & Khang LLP (the “Firm”) reminds investors in CorMedix, Inc.
(“CorMedix” or the “Company”) (NYSE: CRMD),
who purchased or otherwise acquired shares between March 12, 2011 and
July 29, 2015, inclusive (the “Class Period”), of the September 4, 2015,
deadline to serve as lead plaintiff in the class action.
If you purchased shares of CorMedix during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by
e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
According to the complaint, the Company allegedly made false and/or
misleading statements and failed to disclose that: (1) the Company’s
reports concerning its partnership discussions and imminent Phase 3
trials for its sole product, Neutrolin, were misleading; (2) studies
touted by CorMedix overstated Neutrolin’s effectiveness; (3) CorMedix
exaggerated the cost effectiveness of Neutrolin compared to established
medical protocols; and (4) CorMedix stock traded at an artificially high
level due to paid stock promoters who were not disclosed in regulatory
filings.
When the truth was revealed to the public, the stock fell over 16% to
close at $4.05 on June 29, 2015.
If you purchased shares of CorMedix during the Class Period you have
until September 4, 2015, to ask the Court to appoint you as lead
plaintiff. If you wish to learn more about this lawsuit, or if you have
any questions concerning this notice or your rights, please contact Joon
M. Khang, a prominent litigator for almost two decades, by telephone:
(949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150903006638/en/
Copyright Business Wire 2015